NCT05986331 2023-09-21
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Biocad
Phase 3 Unknown
Clinical Trials
13 trialsNCT05783882 2023-03-24
FLAT
Biocad
Phase 3 Unknown
NCT03435302 2018-02-19
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 3 Unknown
NCT00477906 2015-12-03
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
AVAX Technologies
Phase 3 Unknown
NCT00006249 2015-02-10
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT00002767 2014-01-06
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00039234 2013-12-18
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002455 2013-08-07
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002763 2011-11-16
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00779714 2008-10-24
ChemoSensMM
University of Wuerzburg
Phase 3 Unknown
NCT00226408 2006-06-21
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Dermatologic Cooperative Oncology Group
Phase 3 Unknown
NCT00052130 2005-06-24
Vaccine Therapy for Patients With Stage III Melanoma
CancerVax Corporation
Phase 3 Unknown
NCT00052156 2005-06-24
Vaccine Therapy for Patients With Stage IV Melanoma
CancerVax Corporation
Phase 3 Unknown